RE:RE:You are amazing ClaridgeShav3 ... We all agree that TLT is a gem, given all we know now. As for the valuation, it all depends on how things will unfold, etc ...
For sure, solid tumor destruction in one 1-hour treatment is never been acheived. And without side-effect, it's unheard of.
If we get 10% of the coverage immuno-therapy drugs have received in the NYTimes, etc ..., then we'll have a happy problem ... ;-)
But lets get more NMIBC data @3-month and @12-month from the first cohort treated @UHN.
TLT has tested its dosimetry software on 6 forms of bladders. Presentations has shown the bladders of patients #1, #2 and #3 of Ph. 1b. 1 was very different than the 2 others and the 2 others were almost identical. Bladder wall preservation is very crucial. The dosimetry software is pivotal for that. Don't know if you saw the type of mathematic formulas in that software but that wasn't elementary school maths! ... lolll